Combination set to transform HCC therapy
- PMID: 32457541
- DOI: 10.1038/s41571-020-0396-9
Combination set to transform HCC therapy
Comment on
-
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. N Engl J Med. 2020. PMID: 32402160 Clinical Trial.
References
Original article
-
- Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020) - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical